Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

被引：0

作者：

Tantawy, Shady I. ^{[1
]}

Timofeeva, Natalia ^{[1
]}

Fujiwara, Hitomi ^{[2
]}

Hatakeyama, Mariko ^{[2
]}

Herrera, Breana ^{[1
]}

Loza, Lizbeth ^{[1
]}

Asami, Tokiko ^{[2
]}

Ohmoto, Hiroshi ^{[2
]}

Miyamoto, Kyoko ^{[3
]}

Nishioka, Yu ^{[2
]}

Arimura, Akinori ^{[3
]}

Sawa, Masaaki ^{[2
]}

Jain, Nitin ^{[4
]}

Gandhi, Varsha ^{[1
,4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[2] Carna Biosci Inc, Kobe, Hyogo, Japan

[3] CarnaBio USA Inc, San Francisco, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189659

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[11] Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
Ghia, Paolo
Dlugosz-Danecka, Monika
Scarfo, Lydia
Jurczak, Wojciech
LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1066 - 1076
[12] Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
Burger, Jan A.
Li, Kelvin W.
Keating, Michael J.
Sivina, Mariela
Amer, Ahmed M.
Garg, Naveen
Ferrajoli, Alessandra
Huang, Xuelin
Kantarjian, Hagop
Wierda, William G.
O'Brien, Susan
Hellerstein, Marc K.
Turner, Scott M.
Emson, Claire L.
Chen, Shih-Shih
Yan, Xiao-Jie
Wodarz, Dominik
Chiorazzi, Nicholas
JCI INSIGHT, 2017, 2 (02):
[13] Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia
Maes, Tamara
Tirapu, Inigo
Mascaro, Cristina
Ortega, Alberto
Estiarte, Angels
Valls, Nuria
Castro-Palomino, Julio
Buesa Arjol, Carlos
Kurz, Guido
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[14] Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
Liu, Yahong
Cheng, Ying
Huang, Gongchao
Xia, Xiangying
Wang, Xingkai
Tian, Hongqi
FRONTIERS IN PHARMACOLOGY, 2023, 14
[15] Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Tam, Constantine S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 32 - 34
[16] Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Elizabeth M. Muhowski
Janani Ravikrishnan
Britten Gordon
Lianbo Yu
Shrilekha Misra
Brandi Walker
Sudharshan Eathiraj
Deepa Sampath
Kerry A. Rogers
John C. Byrd
Jennifer A. Woyach
Journal of Hematology & Oncology, 15
[17] Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Muhowski, Elizabeth M.
Ravikrishnan, Janani
Gordon, Britten
Yu, Lianbo
Misra, Shrilekha
Walker, Brandi
Eathiraj, Sudharshan
Sampath, Deepa
Rogers, Kerry A.
Byrd, John C.
Woyach, Jennifer A.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[18] Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
Johannessen, Liv
Ke, Nan
Sawant, Priyanka
Dworakowski, Wojciech
D'Ippolito, Anthony
Hu, Shanhu
Rajagopal, Nisha
Eaton, Matthew
Hodgson, Graeme
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[19] Preclinical testing of a novel Axl-kinase inhibitor in Chronic Lymphocytic Leukemia
Goebel, M.
Moellmann, M.
Goergens, A.
Huettmann, A.
Duehrsen, U.
Giebel, B.
Unger, A.
Choidas, A.
Duerig, J.
ONKOLOGIE, 2013, 36 : 172 - 172
[20] Preclinical Testing of a Novel Axl-Kinase Inhibitor in Chronic Lymphocytic Leukemia
Goebel, Maria
Moellmann, Michael
Goergens, Andre
Duehrsen, Ulrich
Huettmann, Andreas
Giebel, Bernd
Unger, Anke
Choidas, Axel
Duerig, Jan
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →